Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...

Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

The 624-subject global study evaluated patients’ progression-free survival (PFS) as a primary endpoint in the intent-to-treat and estrogen receptor 1-mutant (ESR1m) populations, while their ...

BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $20 from $82 and keeps an Outperform rating on the ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

Arvinas and Pfizer will share the costs and profits of the development and commercialization of vepdegestrant, which has ...

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...